enzastaurin + lomustine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma
Trial Timeline
Jan 1, 2006 → May 1, 2014
NCT ID
NCT00295815About enzastaurin + lomustine
enzastaurin + lomustine is a phase 3 stage product being developed by Eli Lilly for Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00295815. Target conditions include Glioblastoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00295815 | Phase 3 | Completed |
Competing Products
20 competing products in Glioblastoma